ATE447569T1 - Pna-monomer und vorstufe - Google Patents
Pna-monomer und vorstufeInfo
- Publication number
- ATE447569T1 ATE447569T1 AT04726242T AT04726242T ATE447569T1 AT E447569 T1 ATE447569 T1 AT E447569T1 AT 04726242 T AT04726242 T AT 04726242T AT 04726242 T AT04726242 T AT 04726242T AT E447569 T1 ATE447569 T1 AT E447569T1
- Authority
- AT
- Austria
- Prior art keywords
- sub
- halogenated
- alkoxy
- alkyl
- oligomers
- Prior art date
Links
- 239000000178 monomer Substances 0.000 title abstract 2
- 239000002243 precursor Substances 0.000 title 1
- 125000003545 alkoxy group Chemical group 0.000 abstract 6
- 125000000217 alkyl group Chemical group 0.000 abstract 6
- 108091093037 Peptide nucleic acid Proteins 0.000 abstract 4
- 229910052794 bromium Inorganic materials 0.000 abstract 4
- 229910052801 chlorine Inorganic materials 0.000 abstract 4
- 229910052731 fluorine Inorganic materials 0.000 abstract 4
- 229910052740 iodine Inorganic materials 0.000 abstract 4
- 229910052736 halogen Inorganic materials 0.000 abstract 2
- 150000002367 halogens Chemical class 0.000 abstract 2
- 150000002825 nitriles Chemical class 0.000 abstract 2
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 abstract 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 2
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 abstract 1
- 239000002253 acid Substances 0.000 abstract 1
- 150000007513 acids Chemical class 0.000 abstract 1
- 150000001370 alpha-amino acid derivatives Chemical class 0.000 abstract 1
- 235000008206 alpha-amino acids Nutrition 0.000 abstract 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 abstract 1
- 230000015572 biosynthetic process Effects 0.000 abstract 1
- 125000000524 functional group Chemical group 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 229910052757 nitrogen Inorganic materials 0.000 abstract 1
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 abstract 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 abstract 1
- 229910052760 oxygen Chemical group 0.000 abstract 1
- 239000001301 oxygen Chemical group 0.000 abstract 1
- 238000002360 preparation method Methods 0.000 abstract 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 abstract 1
- 125000006239 protecting group Chemical group 0.000 abstract 1
- 229910052717 sulfur Inorganic materials 0.000 abstract 1
- 239000011593 sulfur Substances 0.000 abstract 1
- 238000003786 synthesis reaction Methods 0.000 abstract 1
- 150000003573 thiols Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
- C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
- C07D271/10—1,3,4-Oxadiazoles; Hydrogenated 1,3,4-oxadiazoles
- C07D271/113—1,3,4-Oxadiazoles; Hydrogenated 1,3,4-oxadiazoles with oxygen, sulfur or nitrogen atoms, directly attached to ring carbon atoms, the nitrogen atoms not forming part of a nitro radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
- C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D263/34—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D263/46—Sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
- C07D473/18—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 one oxygen and one nitrogen atom, e.g. guanine
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Plural Heterocyclic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Thiazole And Isothizaole Compounds (AREA)
- Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
- Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
- Polyoxymethylene Polymers And Polymers With Carbon-To-Carbon Bonds (AREA)
- Macromolecular Compounds Obtained By Forming Nitrogen-Containing Linkages In General (AREA)
- Polymers With Sulfur, Phosphorus Or Metals In The Main Chain (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US49079203P | 2003-07-28 | 2003-07-28 | |
| PCT/IB2004/050406 WO2005009998A1 (en) | 2003-07-28 | 2004-04-07 | Pna monomer and precursor |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE447569T1 true ATE447569T1 (de) | 2009-11-15 |
Family
ID=34102993
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT04726242T ATE447569T1 (de) | 2003-07-28 | 2004-04-07 | Pna-monomer und vorstufe |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US7211668B2 (de) |
| EP (1) | EP1651642B1 (de) |
| JP (1) | JP4441535B2 (de) |
| KR (2) | KR20070040420A (de) |
| CN (1) | CN1829714B (de) |
| AT (1) | ATE447569T1 (de) |
| DE (1) | DE602004023951D1 (de) |
| DK (1) | DK1651642T3 (de) |
| WO (1) | WO2005009998A1 (de) |
Families Citing this family (83)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20030084444A (ko) * | 2002-04-26 | 2003-11-01 | 주식회사 파나진 | Ｐｎａ 올리고머를 합성하기 위한 신규한 단량체 및 그의제조방법 |
| AU2006213686A1 (en) | 2005-02-09 | 2006-08-17 | Avi Bio Pharma, Inc. | Antisense composition and method for treating muscle atrophy |
| US8198039B2 (en) * | 2007-09-04 | 2012-06-12 | University of Pittsburgh—of the Commonwealth System of Higher Education | Biosensors and related methods |
| KR101072899B1 (ko) * | 2008-01-21 | 2011-10-17 | 주식회사 파나진 | 아미노산 스페이서가 결합된 펩티드 핵산의 합성 및 그의응용 |
| KR101360037B1 (ko) * | 2008-12-02 | 2014-02-07 | 현대자동차주식회사 | 차량용 ｌｎｇ 연료 탱크 |
| CA2764158A1 (en) | 2009-06-01 | 2010-12-09 | Halo-Bio Rnai Therapeutics, Inc. | Polynucleotides for multivalent rna interference, compositions and methods of use thereof |
| JP5991922B2 (ja) | 2009-11-13 | 2016-09-14 | サレプタ セラピューティクス， インコーポレイテッド | アンチセンス抗ウイルス性化合物およびインフルエンザウイルス感染を処置するための方法 |
| US20120309684A1 (en) | 2009-11-30 | 2012-12-06 | Isis Innovation Limited | Conjugates for delivery of biologically active compounds |
| WO2011112516A1 (en) | 2010-03-08 | 2011-09-15 | Ico Therapeutics Inc. | Treating and preventing hepatitis c virus infection using c-raf kinase antisense oligonucleotides |
| EP2545173A2 (de) | 2010-03-12 | 2013-01-16 | Sarepta Therapeutics, Inc. | Antisense-modulation von nukleären hormonrezeptoren |
| AU2011248625B2 (en) | 2010-04-26 | 2017-01-05 | Pangu Biopharma Limited | Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of cysteinyl-tRNA synthetase |
| JP6294074B2 (ja) | 2010-04-27 | 2018-03-14 | エータイアー ファーマ， インコーポレイテッド | イソロイシルｔＲＮＡ合成酵素のタンパク質フラグメントに関連した治療用、診断用および抗体組成物の革新的発見 |
| CN103097524B (zh) | 2010-04-28 | 2016-08-03 | Atyr医药公司 | 与丙氨酰-tRNA合成酶的蛋白片段相关的治疗、诊断和抗体组合物的创新发现 |
| AU2011248457B2 (en) | 2010-04-29 | 2017-02-16 | Pangu Biopharma Limited | Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of valyl tRNA synthetases |
| CA2797374C (en) | 2010-04-29 | 2021-02-16 | Pangu Biopharma Limited | Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of asparaginyl trna synthetases |
| WO2011150279A2 (en) | 2010-05-27 | 2011-12-01 | Atyr Pharma, Inc. | Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of glutaminyl-trna synthetases |
| WO2011140135A2 (en) | 2010-05-03 | 2011-11-10 | Atyr Pharma, Inc. | Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of methionyl-trna synthetases |
| WO2011139986A2 (en) | 2010-05-03 | 2011-11-10 | Atyr Pharma, Inc. | Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of arginyl-trna synthetases |
| CA2797977C (en) | 2010-05-03 | 2019-08-20 | Atyr Pharma, Inc. | Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of phenylalanyl-alpha-trna synthetases |
| CA2798139C (en) | 2010-05-04 | 2019-09-24 | Atyr Pharma, Inc. | Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of p38 multi-trna synthetase complex |
| ES2816898T3 (es) | 2010-05-13 | 2021-04-06 | Sarepta Therapeutics Inc | Compuestos que modulan la actividad de señalización de las interleucinas 17 y 23 |
| CN103200953B (zh) | 2010-05-14 | 2017-02-15 | Atyr 医药公司 | 与苯丙氨酰‑β‑tRNA合成酶的蛋白片段相关的治疗、诊断和抗体组合物的创新发现 |
| CN103096914B (zh) | 2010-05-17 | 2015-08-12 | Atyr医药公司 | 与亮氨酰-tRNA合成酶的蛋白片段相关的治疗、诊断和抗体组合物的创新发现 |
| AU2011289831C1 (en) | 2010-07-12 | 2017-06-15 | Pangu Biopharma Limited | Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of glycyl-tRNA synthetases |
| CN103108650A (zh) | 2010-08-25 | 2013-05-15 | Atyr医药公司 | 与酪氨酰-tRNA合成酶的蛋白片段相关的治疗、诊断和抗体组合物的创新发现 |
| EP2732035A2 (de) | 2011-07-15 | 2014-05-21 | Sarepta Therapeutics, Inc. | Verfahren und zusammensetzungen zur manipulation der übersetzung von proteinisoformen aus alternativen initiierungsstellen |
| US20130085139A1 (en) | 2011-10-04 | 2013-04-04 | Royal Holloway And Bedford New College | Oligomers |
| WO2013086441A2 (en) | 2011-12-08 | 2013-06-13 | Sarepta Therapeutics, Inc. | Oligonucleotide analogues targeting human lmna |
| EP2812344A4 (de) | 2012-02-07 | 2015-10-28 | Vibrant Holdings Llc | Substrate, peptidarrays und verfahren |
| NZ702539A (en) * | 2012-05-31 | 2016-11-25 | Phenex Pharmaceuticals Ag | Carboxamide or sulfonamide substituted thiazoles and related derivatives as modulators for the orphan nuclear receptor ror[gamma] |
| US10006909B2 (en) | 2012-09-28 | 2018-06-26 | Vibrant Holdings, Llc | Methods, systems, and arrays for biomolecular analysis |
| CN103145714A (zh) * | 2013-03-13 | 2013-06-12 | 苏州维泰生物技术有限公司 | 公斤级合成pna的方法 |
| KR102275504B1 (ko) | 2013-09-05 | 2021-07-09 | 사렙타 쎄러퓨틱스, 인코퍼레이티드 | 산성 알파-글루코시다제 내 안티센스-유도된 엑손2 포함 |
| EP3221445B1 (de) | 2014-11-20 | 2021-07-14 | The Regents of The University of California | Zusammensetzungen und verfahren in zusammenhang mit hämatologischer erholung |
| MA41795A (fr) | 2015-03-18 | 2018-01-23 | Sarepta Therapeutics Inc | Exclusion d'un exon induite par des composés antisens dans la myostatine |
| US10849917B2 (en) | 2015-06-01 | 2020-12-01 | Sarepta Therapeutics, Inc. | Antisense-induced exon exclusion in type VII collagen |
| WO2017035278A1 (en) | 2015-08-24 | 2017-03-02 | Halo-Bio Rnai Therapeutics, Inc. | Polynucleotide nanoparticles for the modulation of gene expression and uses thereof |
| WO2017062835A2 (en) | 2015-10-09 | 2017-04-13 | Sarepta Therapeutics, Inc. | Compositions and methods for treating duchenne muscular dystrophy and related disorders |
| EP3377630A4 (de) | 2015-11-16 | 2020-01-01 | Olix Pharmaceuticals, Inc. | Behandlung von altersbedingter makuladegeneration mit auf myd88 oder tlr3 abzielenden rna-komplexen |
| JP6944942B2 (ja) | 2016-02-02 | 2021-10-06 | オリックス ファーマシューティカルズ，インコーポレーテッド | ＩＬ４Ｒα、ＴＲＰＡ１、またはＦ２ＲＬ１を標的とするＲＮＡ複合体を用いたアトピー性皮膚炎および喘息の治療 |
| MY200252A (en) | 2016-04-18 | 2023-12-16 | Sarepta Therapeutics Inc | Antisense oligomers and methods of using the same for treating diseases associated with the acid alpha-glucosidase gene |
| WO2017190041A1 (en) | 2016-04-29 | 2017-11-02 | Sarepta Therapeutics, Inc. | Oligonucleotide analogues targeting human lmna |
| AU2017290231A1 (en) | 2016-06-30 | 2019-02-07 | Sarepta Therapeutics, Inc. | Exon skipping oligomers for muscular dystrophy |
| WO2018017814A1 (en) | 2016-07-20 | 2018-01-25 | President And Fellows Of Harvard College | Peptidoglycan glycosyltransferase inhibitors of sed proteins for treating bacterial infections |
| US11202818B2 (en) | 2016-09-14 | 2021-12-21 | President And Fellows Of Harvard College | Methods and compositions for modulating erythropoiesis |
| WO2018112033A1 (en) | 2016-12-13 | 2018-06-21 | President And Fellows Of Harvard College | Methods and compositions for targeting tumor-infiltrating tregs |
| EP3554552B1 (de) | 2016-12-19 | 2022-08-17 | Sarepta Therapeutics, Inc. | Exon-skipping-oligomerkonjugate für muskeldystrophie |
| LT3554553T (lt) | 2016-12-19 | 2022-08-25 | Sarepta Therapeutics, Inc. | Egzoną šalinantys oligomero konjugatai nuo raumenų distrofojos |
| CN117298290A (zh) | 2016-12-19 | 2023-12-29 | 萨勒普塔医疗公司 | 用于肌肉萎缩症的外显子跳跃寡聚体缀合物 |
| CN110536694A (zh) | 2017-04-20 | 2019-12-03 | Atyr 医药公司 | 用于治疗肺部炎症的组合物和方法 |
| WO2018218250A2 (en) | 2017-05-26 | 2018-11-29 | Vibrant Holdings, Llc | Photoactive compounds and methods for biomolecule detection and sequencing |
| EA201991450A1 (ru) | 2017-09-22 | 2019-12-30 | Сарепта Терапьютикс, Инк. | Конъюгаты олигомеров для пропуска экзона при мышечной дистрофии |
| EP3687577A1 (de) | 2017-09-28 | 2020-08-05 | Sarepta Therapeutics, Inc. | Kombinationstherapien zur behandlung von muskeldystrophie |
| JP2020536060A (ja) | 2017-09-28 | 2020-12-10 | サレプタ セラピューティクス， インコーポレイテッド | 筋ジストロフィーを処置するための併用療法 |
| JP2020536057A (ja) | 2017-09-28 | 2020-12-10 | サレプタ セラピューティクス， インコーポレイテッド | 筋ジストロフィーを処置するための併用療法 |
| WO2019079637A2 (en) | 2017-10-18 | 2019-04-25 | Sarepta Therapeutics, Inc. | ANTISENSE OLIGOMERIC COMPOUNDS |
| CA3099046A1 (en) | 2018-05-09 | 2019-11-14 | Vibrant Holdings, Llc | Methods of synthesizing a polynucleotide array using photoactivated agents________________________________________________________ |
| US10758629B2 (en) | 2018-05-29 | 2020-09-01 | Sarepta Therapeutics, Inc. | Exon skipping oligomer conjugates for muscular dystrophy |
| EP3806868A4 (de) | 2018-06-13 | 2022-06-22 | Sarepta Therapeutics, Inc. | Exon-skipping-oligomere für muskeldystrophie |
| TW202020153A (zh) | 2018-07-27 | 2020-06-01 | 美商薩羅塔治療公司 | 用於肌肉萎縮症之外顯子跳躍寡聚物 |
| US11273137B2 (en) | 2018-09-04 | 2022-03-15 | Board Of Trustees Of Michigan State University | Methods and compositions to prevent and treat disorders associated with mutations in the ODC1 gene |
| IL321667A (en) | 2018-12-13 | 2025-08-01 | Sarepta Therapeutics Inc | Exon skipping oligomer conjugates for muscular dystrophy |
| JP2022523779A (ja) | 2019-03-12 | 2022-04-26 | プレジデント アンド フェローズ オブ ハーバード カレッジ | 癌を処置するための方法および組成物 |
| US20220193246A1 (en) | 2019-04-18 | 2022-06-23 | Sarepta Therapeutics, Inc. | Compositions for treating muscular dystrophy |
| WO2020252257A1 (en) | 2019-06-12 | 2020-12-17 | President And Fellows Of Harvard College | Methods and compositions for modulation of an interspecies gut bacterial pathway for levodopa metabolism |
| KR20210082091A (ko) | 2019-12-24 | 2021-07-02 | 주식회사 시선바이오머티리얼스 | 개질된 감마탄소 골격 화합물 및 이의 제조방법 |
| KR102403904B1 (ko) | 2019-12-24 | 2022-06-02 | 주식회사 시선바이오머티리얼스 | 용액공정상 pna 올리고머의 제조방법 |
| CA3167369A1 (en) | 2020-03-04 | 2021-09-10 | Tara YOUNG | Methods and compositions for sensitization of tumor cells to immune therapy |
| EP4157264A4 (de) | 2020-05-27 | 2024-06-19 | The Regents of the University of California | Zusammensetzungen und verfahren zur transdifferenzierung von zellen |
| WO2022056454A2 (en) | 2020-09-14 | 2022-03-17 | President And Fellows Of Harvard College | Methods and compositions for treating hpv-positive cancers |
| IL301306A (en) | 2020-09-16 | 2023-05-01 | Harvard College | Methods of treating an individual that has failed an anti-pd-1/anti-pd-l1 therapy |
| JP2024537711A (ja) | 2021-09-30 | 2024-10-16 | サレプタ セラピューティクス， インコーポレイテッド | １つ以上の脱塩基ユニットを有するアンチセンスオリゴヌクレオチド |
| WO2023070086A1 (en) | 2021-10-22 | 2023-04-27 | Sarepta Therapeutics, Inc. | Morpholino oligomers for treatment of peripheral myelin protein 22 related diseases |
| US20250011767A1 (en) | 2021-11-18 | 2025-01-09 | Circularis Biotechnologies, Inc. | Compositions and methods for production of circular nucleic acid molecules |
| WO2023150181A1 (en) | 2022-02-01 | 2023-08-10 | President And Fellows Of Harvard College | Methods and compositions for treating cancer |
| KR20250054842A (ko) | 2022-07-29 | 2025-04-23 | 리제너론 파마슈티칼스 인코포레이티드 | 뇌 및 근육으로의 트랜스페린 수용체(tfr)-매개 전달을 위한 조성물 및 방법 |
| JP2025533454A (ja) | 2022-09-21 | 2025-10-07 | サレプタ セラピューティクス， インコーポレイテッド | Ｄｍｄアンチセンスオリゴヌクレオチド介在性エクソンスキッピング効率 |
| CN120693347A (zh) | 2022-11-04 | 2025-09-23 | 瑞泽恩制药公司 | 钙电压门控通道辅助亚基γ1(CACNG1)结合蛋白和CACNG1介导的向骨骼肌的递送 |
| WO2024107765A2 (en) | 2022-11-14 | 2024-05-23 | Regeneron Pharmaceuticals, Inc. | Compositions and methods for fibroblast growth factor receptor 3-mediated delivery to astrocytes |
| JP2025539043A (ja) | 2022-11-14 | 2025-12-03 | バイオンテック・エスイー | Ｒｎａキャッピング効率アッセイ |
| TW202442246A (zh) | 2023-04-27 | 2024-11-01 | 美商薩羅塔治療公司 | 用於治療慢性腎病之反義寡聚物 |
| WO2024231285A1 (en) | 2023-05-05 | 2024-11-14 | BioNTech SE | Method of analysing contaminants in rna products by ion-pair chromatography |
| AU2024362420A1 (en) | 2023-10-18 | 2026-04-23 | Murdoch University | Antisense oligomers for treatment of centronuclear myopathies |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3635956A (en) * | 1968-03-01 | 1972-01-18 | Squibb & Sons Inc | Benzothiazines related compounds derivatives and salts thereof |
| IT1059127B (it) * | 1976-04-15 | 1982-05-31 | Montedison Spa | Eteri e tioeteri benzilici o feni lici a catena alifatica lineare con terminale alogenato ad attivi ta ormonica giovanile e acaric/da |
| US5435939A (en) * | 1993-07-07 | 1995-07-25 | Isp Investments Inc. | Stable emulsifiable gel matrix and aqueous macroemulsion prepared therefrom |
| US5539083A (en) * | 1994-02-23 | 1996-07-23 | Isis Pharmaceuticals, Inc. | Peptide nucleic acid combinatorial libraries and improved methods of synthesis |
| DE69933770D1 (de) | 1998-07-09 | 2006-12-07 | Biocept Inc | Verfahren zur verwendung einer universellen bibliothek von peptid-nukleinsäuren zur optimierung der dns-hybridisierung |
| KR100604688B1 (ko) * | 2001-05-15 | 2006-07-25 | 미쓰이 가가쿠 가부시키가이샤 | 아크릴산에스테르 화합물 및 그 용도 |
| KR100464261B1 (ko) | 2002-01-24 | 2005-01-03 | 주식회사 파나진 | Ｐｎａ 올리고머를 합성하기 위한 신규한 단량체 및 그의제조방법 |
| KR20030084444A (ko) | 2002-04-26 | 2003-11-01 | 주식회사 파나진 | Ｐｎａ 올리고머를 합성하기 위한 신규한 단량체 및 그의제조방법 |
-
2004
- 2004-04-06 US US10/819,769 patent/US7211668B2/en not_active Expired - Lifetime
- 2004-04-07 DK DK04726242T patent/DK1651642T3/da active
- 2004-04-07 JP JP2006521712A patent/JP4441535B2/ja not_active Expired - Fee Related
- 2004-04-07 EP EP04726242A patent/EP1651642B1/de not_active Expired - Lifetime
- 2004-04-07 KR KR1020077006779A patent/KR20070040420A/ko not_active Withdrawn
- 2004-04-07 DE DE602004023951T patent/DE602004023951D1/de not_active Expired - Lifetime
- 2004-04-07 AT AT04726242T patent/ATE447569T1/de not_active IP Right Cessation
- 2004-04-07 WO PCT/IB2004/050406 patent/WO2005009998A1/en not_active Ceased
- 2004-04-07 KR KR1020067002202A patent/KR100752552B1/ko not_active Expired - Lifetime
- 2004-04-07 CN CN2004800220716A patent/CN1829714B/zh not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| EP1651642A4 (de) | 2006-11-29 |
| EP1651642A1 (de) | 2006-05-03 |
| DE602004023951D1 (de) | 2009-12-17 |
| DK1651642T3 (da) | 2009-12-14 |
| KR20070040420A (ko) | 2007-04-16 |
| EP1651642B1 (de) | 2009-11-04 |
| US20050026930A1 (en) | 2005-02-03 |
| CN1829714A (zh) | 2006-09-06 |
| WO2005009998A1 (en) | 2005-02-03 |
| CN1829714B (zh) | 2012-05-30 |
| US7211668B2 (en) | 2007-05-01 |
| JP4441535B2 (ja) | 2010-03-31 |
| JP2007500184A (ja) | 2007-01-11 |
| KR20060037415A (ko) | 2006-05-03 |
| KR100752552B1 (ko) | 2007-08-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK1651642T3 (da) | PNA-monomer og prækursor | |
| ATE453631T1 (de) | Pna-monomer und vorstufe | |
| DE60328866D1 (de) | Peptid-nukleinsäure-oligomere aus 1-benzol sulfonyl-3-amino säure seitenkette-4-(2-nukleo base(acetyl))piperazin-2-onen | |
| TWI266761B (en) | Benzoylsulfonamides and sulfonylbenzamidines for use as antitumour agents | |
| NO20062339L (no) | Hepatitt C virus-inhibitoerer | |
| NO20044807L (no) | Heratitt C virus inhibitorer | |
| NO20062267L (no) | Hepatitt C virus inhibitorer | |
| BR0211078A (pt) | Compostos, processo papa a preparação e uso dos mesmos, composições herbicidas, e, método para o controle de ervas daninhas em áreas cultivadas | |
| TW200635585A (en) | Monocyclic substituted methanones | |
| CY1111349T1 (el) | Καρβαμιδικες ενωσεις προς χρηση στη θεραπεια του πονου | |
| ATE277889T1 (de) | Aminobenzophenone als inhibitoren von il-1beta und tnf-alpha | |
| ATE277897T1 (de) | Aminobenzophenone als inhibitoren von il-1beta und tnf-alpha | |
| ATE277891T1 (de) | Aminobenzophenone als inhibitoren von il-1beta und tnf-alpha | |
| DK0618193T3 (da) | Nitrogenholdige, bicycliske derivater som prolyl-endopeptidaseinhibitorer | |
| WO2004087647A3 (fr) | Derives de quinoleines-4-substituees avec une activite antimicrobienne | |
| DK1368021T3 (da) | Carbamatforbindelser til anvendelse ved forebyggelse eller behandling af bipolær sygdom | |
| DK1408953T3 (da) | Carbamatforbindelser til anvendelse til forebyggelse eller behandling af bipolær sygdom | |
| JP2002501043A5 (de) | ||
| DE60005689D1 (de) | Neue aminobenzophenone | |
| DE60125053D1 (de) | Cephem verbindungen und diese enthaltende esbl nachweisreagenzien | |
| WO2005016916A3 (fr) | Quinolines substituées comme antimicrobiens | |
| DE602004009306D1 (de) | 3,4-dihydro-1h-chinolin-2-onderivate als norepinephrin-wiederaufnahme-hemmern | |
| HRP20090012T3 (en) | 2h or 3h-benzo[e]indazol-1-yle carbamate derivatives, the preparation and therapeutic use thereof | |
| DE50004320D1 (de) | Stabilisierte zusammensetzungen von o- und n-vinylverbindungen und verwendung von ammoniumsalzen als stabilisierungsmittel | |
| DE602005001704D1 (de) | Verfahren zur herstellung von alkoxycarbonylmethoxy-cyclopentanen |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |